Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell
carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%,
and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor
after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the
efficacy and safety of chemoradiation therapy in patients with recurrences after radical
surgery or palliative surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Anyang Cancer Hospital Anyang Tumor Hospital Beijing Cancer Hospital Fujian Cancer Hospital Hebei Medical University Fourth Hospital The First Affiliated Hospital with Nanjing Medical University Tianjin Medical University Cancer Institute and Hospital